Pyrimidine TBK/IKKe inhibitor compounds and uses thereof

A compound of formula I,

• or a pharmaceutically acceptable salt thereof;
• wherein
• R1 is hydrogen, optionally substituted C1-6 aliphatic, —OR, or halogen;
• Ring Z is phenyl or a 5-6-membered heteroaryl having 1, 2, or 3 nitrogens;
• each R2 is independently
• each R3 is independently —R, halogen, —OR, —SR, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
• Ring A is phenyl or a 5-6-membered heteroaryl having 1, 2, or 3 nitrogens;
• R4 is —R, halogen, —OR, —SR, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
• each R5 is independently —R, halogen, —OR, —SR, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
• each R is independently hydrogen, C1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• or a 6-12 membered spiro, fused, or bridged bicyclic carbocyclic or heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each of which is optionally substituted;
• or
• two R groups on the same atom are taken together with the atom to which they are attached to form a C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each of which is optionally substituted;
• n is 1 or 2;
• p is 0, 1, or 2;
• and
• q is 0, 1, or 2.